Search the Newsreel

Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com

This article reports on Neumora Therapeutics Inc.'s Form 8K filing for August 14. The filing contains important company information for investors, who should review the full document for complete details. The stock symbol for Neumora Therapeutics Inc. is NMRA, and it experienced a -7.51% …

Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Neumora Therapeutics Inc is projected to report an earnings loss of 24 cents per share. This information is provided as an earnings preview.

Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA

Perceptive Advisors LLC has acquired a significant stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA), purchasing over 5.1 million shares valued at approximately $9.95 million. This investment represents about 2.75% of the company, contributing to the 47.65% institutional ownership of Neumora Therapeutics. While analyst sentiment is …

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

This article summarizes recent analyst ratings for three healthcare companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY), and Fortrea Holdings Inc. (FTRE). Needham maintained a Buy rating for Bicycle Therapeutics, William Blair maintained a Buy for Alnylam Pharma, and Bank of America Securities maintained a …

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, I

Levi & Korsinsky LLP has announced a class action lawsuit against Neumora Therapeutics, Inc. (NMRA) on behalf of shareholders who suffered losses. The lawsuit alleges that Neumora made false statements and concealed information regarding its Phase Three Program and Phase Two trial data for …

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $6.57 against a current price of $1.65. While several analysts recently lowered their price targets, the general sentiment remains positive. Institutional investors hold …

Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA

Neumora Therapeutics Inc. (NMRA) Q1 2026 Earnings: Narrower-Than-Expected Loss on Cost Discipline, Shares Slip - Margin Compression Risk

Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday

Neumora Therapeutics (NMRA) is projected to release its Q2 2026 earnings before market open on August 5th, with analysts anticipating a loss of $0.23 per share. The company previously exceeded estimates with a $0.30-per-share loss. Despite recent target price reductions, analysts maintain a "Moderate …

H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7

H.C. Wainwright has reiterated its Buy rating for Neumora Therapeutics (NMRA.US) and maintained a target price of $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Neumora Therapeutics Shares Rise on Positive Obesity Drug Results

Neumora Therapeutics (NMRA) saw its shares rise by 1.20%, indicating positive market reaction to an unspecified event. This news was reported alongside Unity Software's (U.US) fourth-quarter financial results, which showed a 35% year-over-year revenue increase to $609 million, exceeding analyst estimates, despite reporting a …

Neumora Therapeutics | 8-K: Current report

This article is a current report (8-K) filed by Neumora Therapeutics. The content consists solely of the word "Document," indicating that it is a placeholder or an incomplete entry for a regulatory filing.

NMRA|Neumora Therapeutics Inc|Price:1.456|Chg%:-0.034

This article provides a detailed financial overview of Neumora Therapeutics Inc. (NMRA), including its stock performance, market capitalization, and key financial statements. It highlights the company's latest earnings, revenue, EPS, and analyst ratings, alongside historical data for income, balance sheet, and cash flow. The …

Neumora Therapeutics Reports Favorable Repeat Toxicology Results for NMRA-215 and Plans IND Submission in Q4 2026

Neumora Therapeutics announced positive pre-clinical toxicology results for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic diseases. This follows a repeat 13-week toxicology study in rats that showed no adverse effects, after discrepancies were found in a prior study. The company plans to …

Neumora's Repeat NMRA-215 Rat Study Found No Unexpected Adverse Findings

Neumora Therapeutics reported favorable results from a repeat 13-week rat toxicology study for its drug candidate NMRA-215, finding no unexpected adverse effects in 162 animals. This follows a previous study where 5 of 142 rats showed adverse findings, which a subsequent audit attributed to …

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease, following a repeat 13-week rat study. The company plans to submit an Investigational New Drug (IND) application in Q4 2026 and initiate a Phase 1 study …

Neumora Therapeutics Inc (NMRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Neumora Therapeutics Inc (NMRA), detailing its current stock price and market capitalization. It highlights that key valuation metrics such as P/E, P/B, and P/CF ratios have not yet been disclosed by the company. The content primarily focuses …

Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Neumora Therapeutics (NASDAQ:NMRA) from a "sell" to a "strong sell," despite the broader analyst consensus remaining a "Moderate Buy." The company, a clinical-stage biopharmaceutical firm focused on CNS disorders, reported a smaller-than-expected quarterly loss. Neumora Therapeutics' stock is trading …

Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRA

Siren L.L.C. significantly increased its stake in Neumora Therapeutics (NASDAQ:NMRA) by 35.1% in the first quarter, purchasing 2.21 million additional shares, bringing its total to 8.50 million shares. Institutional investors collectively own 47.65% of Neumora's stock, with other firms like Millennium Management LLC and …

Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7. 2025 - NMRA

Faruqi & Faruqi, LLP is reminding investors of Neumora Therapeutics (NASDAQ: NMRA) about a pending class action lawsuit with a lead plaintiff deadline of April 7, 2025. The lawsuit alleges that Neumora and its executives made misleading statements regarding the company's Phase Two Trial …

Neumora Therapeutics (NMRA) AGM 2026 Summary

The Neumora Therapeutics (NMRA) 2026 Annual General Meeting (AGM) took place virtually on May 30, 2026. During the meeting, Class III director nominees were re-elected, Ernst & Young LLP was ratified as the independent auditor, and executive officer compensation was approved on an advisory …

Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)

Neumora Therapeutics (NASDAQ:NMRA) experienced unusually heavy options trading on Thursday, with investors purchasing 12,405 put options, a 1,007% increase over its daily average. The stock's price fell by 1.0% to $1.61, and the company, a small-cap biotech with a market value of $298.9 million, …

Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation

Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy

Neumora Therapeutics, Inc. Actuals & Estimates (NASDAQ:NMRA)

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

What date does Neumora Therapeutics, Inc.'s (NMRA) report Earnings - Earnings Calendar & Announcement

Should I buy Neumora Therapeutics, Inc. (NMRA)

NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials

Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in